drugset / Trial / NCT04942665

Low Dose ICG for Biliary Tract and Tumor Imaging

NCT04942665

RandomizedParallel-groupDouble-blindDiagnostic

Summary

Near-infrared fluorescence (NIRF) imaging after an intravenous injection of indocyanine green (ICG) allows for the intraoperative identification of liver anatomy. The investigators have new data that a much lower dose improves this visualization. Confirmation of this hypothesis would mean that ICG can be administered on the same day of surgery in order to augment real-time intraoperative visualization, thereby providing a safe, feasible, and cost-effective strategy for the surgical treatment of liver disease.

Timeline

Start
2021-09-15
Primary completion
2022-09-15
Completion
2023-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Indocyanine Green Diagnostic / imaging agent 0.05 mg Intravenous
Subject Indocyanine Green Diagnostic / imaging agent 2.5 mg Intravenous